Downloads provided by UsageCounts
2005_FDA_r_s_F11-7942 DAP-Efficacy-Studies-005-007-013-015 We obtained Gardasil® Data Analysis Plans (DAPs) from the FDA through Freedom of Information Act (FOIA) request. The above linked DAP introduced modifications in the study participants populations. Instead of “per protocol analysis” for the outcome CIN 2+ irrespective of HPV type, this DAP introduced a post-hoc subgroup analysis (subgroup of subjects negatives to 14 HPV types, called RMITT-2).
Gardasil, HPV Vaccine, Approval, Data Analysis Plan
Gardasil, HPV Vaccine, Approval, Data Analysis Plan
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
| views | 208 | |
| downloads | 14 |

Views provided by UsageCounts
Downloads provided by UsageCounts